Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal

Zhenqing Wang; Liang Chen; Yiqun Ma; Xilei Li; Annan Hu; Huiren Wang; Wenxing Wang; Xiaomin Li; Bo Tian; Jian Dong

doi:10.1186/s12951-021-00975-5

ScienceGate Book Chapters

JOURNAL ARTICLE

Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal

Zhenqing Wang Liang Chen Yiqun Ma Xilei Li Annan Hu Huiren Wang Wenxing Wang Xiaomin Li Bo Tian Jian Dong

Year: 2021 Journal: Journal of Nanobiotechnology Vol: 19 (1)Pages: 243-243 Publisher: BioMed Central

DOI: 10.1186/s12951-021-00975-5

Get Full-Text PDF Get Analytical Report

Keywords:

Immunotherapy Cytotoxic T cell Cancer research Immunogenic cell death Tumor microenvironment Cancer immunotherapy Immune checkpoint Immune system Blockade T cell CD8 Medicine Immunology Chemistry Receptor Internal medicine

Metrics

Cited By

5.64

FWCI (Field Weighted Citation Impact)

Refs

0.96

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Nanoplatforms for cancer theranostics

Physical Sciences → Engineering → Biomedical Engineering

Cancer Immunotherapy and Biomarkers

Health Sciences → Medicine → Oncology

Brain Metastases and Treatment

Health Sciences → Medicine → Pulmonary and Respiratory Medicine

Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal

Metrics

Citation History

Topics

Related Documents

Additional file 1 of Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal

Additional file 1 of Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal

Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

PD-L1 antibody conjugated dihydrotanshinone I-loaded polymeric nanoparticle for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

Enhanced Immunogenic Cell Death by Apoptosis/Ferroptosis Hybrid Pathway Potentiates PD-L1 Blockade Cancer Immunotherapy